Litigation Details for Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2016)

Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2016)

Docket		Date Filed	2016-09-22
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To
Patents	9,375,405
Link to Docket	External link to docket

Details for Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-09-22	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,375,405 B2. (nmg) (Entered:…22 September 2016 1:16-cv-00855 830 Patent None District Court, D. Delaware	External link to document

Amgen Inc. v. Watson Laboratories, Inc. Litigation Summary and Patent Analysis, 1:16-cv-00855

Last updated: August 9, 2026

Amgen Inc. v. Watson Laboratories, Inc., No. 1:16-cv-00855, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Watson's proposed generic version of Sensipar, Amgen's cinacalcet hydrochloride product. Amgen asserted U.S. Patent No. 6,211,244, which covered methods of treating hyperparathyroidism with cinacalcet. The case formed part of a broader set of Amgen lawsuits against generic manufacturers following Paragraph IV challenges to Sensipar's Orange Book-listed patent.

The litigation materially reduced Amgen's exclusivity position. The asserted patent was found invalid as obvious in related Delaware proceedings involving the same patent and generic cinacalcet products. FDA approvals of generic cinacalcet followed, creating direct erosion of Sensipar revenue after the branded product's primary commercial protection ended.

What drug and patent were involved in Amgen v. Watson?

The case involved Sensipar tablets, whose active ingredient is cinacalcet hydrochloride. Sensipar is approved for:

• Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
• Hypercalcemia in patients with parathyroid carcinoma.
• Severe hypercalcemia in patients with primary hyperparathyroidism who cannot undergo parathyroidectomy.

Amgen asserted U.S. Patent No. 6,211,244, titled "Methods of treating hyperparathyroidism." The patent generally covered administering a calcimimetic compound, including cinacalcet, to treat hyperparathyroidism.

Item	Detail
Branded drug	Sensipar
Active ingredient	Cinacalcet hydrochloride
Dosage form	Immediate-release tablets
Plaintiff	Amgen Inc.
Defendant	Watson Laboratories, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:16-cv-00855
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Primary asserted patent	U.S. Patent No. 6,211,244
Patent subject matter	Methods of treating hyperparathyroidism
Regulatory trigger	Abbreviated New Drug Application and Paragraph IV certification

Watson Laboratories was part of the Actavis/Allergan generic pharmaceutical organization. The defendant's ANDA sought approval to market generic cinacalcet tablets before the asserted patent's listed expiration date.

When was Amgen v. Watson filed and what triggered the lawsuit?

Amgen filed the case in 2016 after receiving Watson's Paragraph IV certification. A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The filing of the lawsuit triggered the 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and later court developments. During the stay, FDA generally could not give final approval to the ANDA unless the stay expired, the patent was held invalid or not infringed, or the litigation was otherwise resolved.

Amgen filed parallel lawsuits against other generic manufacturers, including Teva Pharmaceuticals, Cipla, and additional ANDA applicants. The cases involved common questions regarding the validity and scope of the '244 patent.

What Orange Book patents protected Sensipar?

Sensipar's principal Orange Book protection included patents directed to the cinacalcet compound and methods of use. The most commercially important method patent in the Watson litigation was U.S. Patent No. 6,211,244.

Patent	General subject matter	Relevance to generic entry
U.S. Patent No. 6,011,068	Calcimimetic compounds, including cinacalcet-related chemistry	Earlier compound protection; its term ended before the later generic launch period
U.S. Patent No. 6,211,244	Methods of treating hyperparathyroidism	Principal patent asserted in the 2016 generic litigation
Later Sensipar-related listings	Various formulations, dosing, or use claims depending on the listing	Potential secondary barriers, but not equivalent to broad compound protection

The '244 patent had a listed expiration in 2021, subject to any applicable patent-term adjustment or pediatric exclusivity. Its practical value depended on whether the claims survived validity challenges and whether the generic applicant's proposed labeling induced infringement.

How strong was Amgen's patent estate?

Amgen's estate was commercially important but legally vulnerable once compound-level protection ended. The '244 patent provided method-of-use coverage rather than broad control over all cinacalcet products. That distinction limited its ability to block generic entry if a generic applicant could use a non-infringing label or establish that the claims were invalid.

The central validity issue was obviousness under 35 U.S.C. § 103. The generic defendants argued that prior art disclosed:

1. Calcimimetic compounds.
2. Cinacalcet or closely related compounds.
3. Treatment of hyperparathyroidism.
4. Dose-ranging and clinical use concepts relevant to the claimed method.

Amgen relied on the asserted claims, the clinical development history, and evidence that the claimed treatment produced meaningful results. The defense position was that the claimed method represented a predictable application of known compounds and known treatment objectives.

The courts treated the patent as vulnerable because the prior art supplied a strong rationale to pursue cinacalcet for hyperparathyroidism. The expected therapeutic objective and the known pharmacology weighed against a finding of non-obviousness.

What did the court decide about the '244 patent?

The Delaware litigation involving Amgen's Sensipar patent resulted in a finding that the asserted claims of the '244 patent were invalid as obvious. The related Federal Circuit proceedings addressed the same patent and the generic cinacalcet disputes. The Federal Circuit affirmed the district court's core invalidity determination in the resulting appellate litigation. Amgen Inc. v. Amneal Pharmaceuticals LLC, 945 F.3d 1368 (Fed. Cir. 2020).

The invalidity ruling removed the principal patent barrier that Amgen had asserted against generic cinacalcet manufacturers. Once the patent could no longer support an injunction, the commercial case for delayed generic entry weakened substantially.

The key legal issues were:

• Whether the prior art supplied a reason to combine known calcimimetic compounds with treatment of hyperparathyroidism.
• Whether a skilled artisan would have had a reasonable expectation of success.
• Whether Amgen's clinical results were unexpected.
• Whether objective indicia, including commercial success and industry activity, supported patentability.
• Whether the proposed generic labeling would induce infringement if the claims were otherwise valid.

The court's conclusion on obviousness made infringement issues less commercially decisive. A patent that is invalid cannot support a pre-launch injunction, even if the accused product would otherwise fall within the claim scope.

What Paragraph IV challenge and generic launch risks did Watson create?

Watson's Paragraph IV filing created three principal risks for Amgen:

Early FDA approval

A successful Paragraph IV defense could have permitted Watson to obtain final FDA approval before the listed patent expiration. The 30-month stay would not permanently prevent approval if the patent were invalidated or the litigation ended in the generic applicant's favor.

Loss of method-of-use protection

If the asserted method claims were invalid, Amgen could not rely on the '244 patent to prevent generic cinacalcet sales. Method patents are particularly exposed where the generic product has multiple medically accepted uses and the labeling can be drafted around patented indications.

Price and share erosion

Cinacalcet tablets are orally administered, chemically synthesized products. They do not present the manufacturing or substitution barriers associated with biologics. Once multiple ANDA applicants receive approval, pharmacy substitution and payer pressure can rapidly reduce branded volume and net price.

What was the litigation timeline?

Date	Event
2016	Amgen filed the Watson action in the District of Delaware after Watson's Paragraph IV certification.
2016-2018	Parallel Sensipar patent actions proceeded against multiple generic manufacturers.
2018	Generic cinacalcet approvals and court decisions materially weakened Amgen's ability to maintain a full market monopoly.
2019-2020	Appeals and related proceedings addressed the validity of the '244 patent.
2020	The Federal Circuit issued its decision in the related Amgen v. Amneal litigation, affirming the core invalidity outcome.
After 2020	Generic cinacalcet became commercially available from multiple manufacturers.

The docket-specific Watson action should be evaluated together with the coordinated Sensipar cases because claim construction, validity evidence, and market-entry consequences were substantially interconnected.

Did Amgen settle with Watson or other generic manufacturers?

Publicly reported Sensipar generic activity involved multiple ANDA applicants and separate litigation outcomes. The commercial result was not a durable Amgen-wide exclusion of generic cinacalcet through 2021. Generic approvals and invalidity decisions reduced the value of any settlement strategy that would have preserved a broad delayed-entry date.

A settlement could still have addressed launch timing, authorized generic supply, damages, or dismissal of individual claims. Such an agreement would not restore an invalid patent or prevent FDA approval after the statutory and judicial barriers were removed. The public record is best understood as a coordinated patent campaign in which the '244 patent ultimately failed to provide reliable exclusionary protection.

How does Sensipar patent risk compare with biosimilar risk?

Sensipar is a small-molecule drug, not a biologic. Watson's product was reviewed through the ANDA pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.

Issue	Sensipar generic	Biosimilar product
Regulatory pathway	ANDA	BLA under section 351(k)
Primary competition	Generic substitution	Biosimilar interchangeability and payer adoption
Patent framework	Hatch-Waxman	Biologics patent dance and related litigation
Manufacturing barrier	Chemical synthesis	Complex biologic manufacturing
Litigation focus	Compound, formulation, method, and labeling patents	Composition, process, formulation, and clinical-use patents
Entry pattern	Multiple applicants can launch after approval	Entry often depends on settlement and manufacturing readiness

The absence of biologic manufacturing complexity made the Sensipar estate more dependent on patent validity and Orange Book strategy.

What revenue exposure did the case create for Amgen?

Sensipar was a major Amgen product before generic entry. Amgen reported Sensipar sales of approximately $1.4 billion in 2017, according to its annual report. Generic approval created immediate exposure across all major indications because cinacalcet tablets are substitutable oral products and dialysis providers exert substantial purchasing pressure (Amgen Inc., 2018).

The revenue risk had four components:

• Volume migration to lower-priced generic tablets.
• Rebate and discount pressure from payers.
• Loss of negotiating leverage with dialysis providers.
• Compression of branded sales before the nominal '244 expiration date.

The patent invalidity decision increased the probability of rapid erosion by removing the legal mechanism for delaying entry.

What manufacturing and intellectual-property barriers remained?

After loss of the '244 patent, remaining barriers were narrower:

• FDA approval of each individual ANDA.
• Demonstration of pharmaceutical equivalence and bioequivalence.
• Active pharmaceutical ingredient sourcing.
• Tablet manufacturing capacity.
• Quality-system compliance.
• Any non-expired formulation or process patents that could be credibly asserted.
• Labeling restrictions for patented indications, if any remained enforceable.

These barriers could affect the timing and scale of individual competitors but were unlikely to preserve Sensipar's prior monopoly. Cinacalcet's small-molecule structure and established manufacturing process limited the practical force of process patents unless they covered a commercially necessary route.

What is the current legal and commercial significance of 1:16-cv-00855?

The Watson case is significant because it illustrates the limits of relying on a late-stage method-of-use patent after compound exclusivity has expired. Amgen's principal patent strategy shifted from controlling the molecule to controlling treatment of hyperparathyroidism. That strategy faced an obviousness challenge based on the predictable relationship between calcimimetic pharmacology and the disease indication.

The case also shows why generic litigation must be analyzed at the coordinated portfolio level. A single docket may not contain every relevant patent, ANDA applicant, settlement, or appellate ruling. The practical market result depends on whether at least one major generic applicant defeats the core patent and whether other defendants remain blocked.

Key Takeaways

• Amgen sued Watson in Delaware in 2016 over a Paragraph IV challenge to Sensipar.
• The principal patent was U.S. Patent No. 6,211,244, covering methods of treating hyperparathyroidism with cinacalcet.
• The asserted method claims were found invalid as obvious in the related Sensipar litigation.
• The Federal Circuit affirmed the core invalidity result in related proceedings.
• The decision removed the principal patent barrier to generic cinacalcet entry.
• Sensipar's small-molecule status allowed ANDA applicants to compete without biosimilar development requirements.
• Amgen faced substantial revenue exposure after generic approvals, given Sensipar's approximately $1.4 billion in 2017 sales.
• The case reduced the commercial value of the remaining Sensipar patent estate and limited Amgen's ability to delay generic competition through method-of-use claims.

FAQs About Amgen v. Watson Laboratories, 1:16-cv-00855

What was Amgen's main patent in the Watson Sensipar case?

Amgen's principal asserted patent was U.S. Patent No. 6,211,244, directed to methods of treating hyperparathyroidism with calcimimetic compounds, including cinacalcet.

Was Watson's generic cinacalcet product a biosimilar?

No. Cinacalcet is a small-molecule drug. Watson's product was subject to the ANDA pathway under the Hatch-Waxman Act.

Why was the Sensipar patent found obvious?

The courts determined that the prior art provided a reason to use known calcimimetic compounds, including cinacalcet-related compounds, to treat hyperparathyroidism with a reasonable expectation of success.

Did the patent case prevent generic Sensipar indefinitely?

No. Generic cinacalcet products entered the market after FDA approvals and the invalidity outcome affecting the '244 patent.

What was the business impact of the case on Amgen?

The case exposed Sensipar to accelerated generic erosion. Amgen's reported 2017 Sensipar sales were approximately $1.4 billion, making the loss of enforceable method-of-use protection commercially material.

References

1. Amgen Inc. v. Amneal Pharmaceuticals LLC, 945 F.3d 1368 (Fed. Cir. 2020).

2. Amgen Inc. v. Watson Laboratories, Inc., No. 1:16-cv-00855, U.S. District Court for the District of Delaware.

3. Amgen Inc. 2017 Annual Report. Thousand Oaks, CA: Amgen Inc., 2018.

4. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Washington, DC: U.S. Department of Health and Human Services.

5. U.S. Patent No. 6,211,244. U.S. Patent and Trademark Office.